Centre Pluridisciplinaire d'Oncologie, Department of Neurosurgery, Service de Radio-Oncologie, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne; Institute of Medical Oncology, University of Bern, Bern; Division d'Oncologie, Hôpitaux Universitaires de Genève, Geneva; Department of Neurology, University Hospital, Zurich, Switzerland; Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels; Department of Clinical Oncology, Katholieke Universiteit Leuven, Leuven, Belgium; Department of Neurosurgery, University Hospital of Cologne, Cologne; Department of Neurosurgery, University of Munich, Munich; Neurologische Universitätsklinik des Knappschaftskrankenhauses Bochum-Langendreer, Ruhr University, Bochum; Friedrich Alexander University, Erlangen; Department of Neurosurgery, Institute of Neuropathology, University of Bonn, Bonn; Merck Serono, Darmstadt; and Department of General Neurology, University of Tübingen, Tübingen, Germany.
J Clin Oncol. 2010 May 3.
Invasion and migration are key processes of glioblastoma and are tightly linked to tumor recurrence. Integrin inhibition using cilengitide has shown synergy with chemotherapy and radiotherapy <i>in vitro</i> and promising activity in recurrent glioblastoma. This multicenter, phase I/IIa study investigated the efficacy and safety of cilengitide in combination with standard chemoradiotherapy in newly diagnosed glioblastoma.
Patients (age >/= 18 to </= 70 years) were treated with cilengitide (500 mg) administered twice weekly intravenously in addition to standard radiotherapy with concomitant and adjuvant temozolomide. Treatment was continued until disease progression or for up to 35 weeks. The primary end point was progression-free survival (PFS) at 6 months.
Fifty-two patients (median age, 57 years; 62% male) were included. Six- and 12-month PFS rates were 69% (95% CI, 54% to 80%) and 33% (95% CI, 21% to 46%). Median PFS was 8 months (95% CI, 6.0 to 10.7 months). Twelve- and 24-month overall survival (OS) rates were 68% (95% CI, 53% to 79%) and 35% (95% CI, 22% to 48%). Median OS was 16.1 months (95% CI, 13.1 to 23.2 months). PFS and OS were longer in patients with tumors with O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation (13.4 and 23.2 months) versus those without MGMT promoter methylation (3.4 and 13.1 months). The combination of cilengitide with temozolomide and radiotherapy was well tolerated, with no additional toxicity. No pharmacokinetic interactions between temozolomide and cilengitide were identified.
Compared with historical controls, the addition of concomitant and adjuvant cilengitide to standard chemoradiotherapy demonstrated promising activity in patients with glioblastoma with MGMT promoter methylation.
PMID: 20439646 [PubMed - as supplied by publisher] Source: National Library of Medicine.
